Delirium: scope consultation (16th April 2008)
NICE have been asked to develop a clinical practice guideline on the diagnosis, prevention and management of delirium for use in the NHS in England and Wales. The draft scope defines what aspects of care the guideline will cover and to whom it will apply. Registered stakeholders for this guideline are invited to submit comments on the scope and may suggest clinical questions that could be answered in the guideline. Closing date for comments is 14th May 2008.
Click here for the Consultation
Click here for the Comments proforma
Critical illness rehabilitation: scope consultation (17th April 2008)
NICE have been asked to develop a clinical practice guideline on Critical illness rehabilitation for use in the NHS in England, Wales and Northern Ireland. The draft scope defines what aspects of care the guideline will cover and to whom it will apply. Registered stakeholders for the Critical illness rehabilitation guideline are invited to submit comments on the scope and may suggest clinical questions that could be answered in the guideline. Closing date for comments is 15th May 2008.
Click here for the Consultation
Click here for the Comments proforma
Surgical site infection: consultation (22nd April 2008)
A clinical practice guideline on surgical site infection is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations via this website. Although individuals and organisations not registered as stakeholders are able to comment, we recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. We work closely with stakeholder organisations and take their views very seriously. Closing date for comments is 16th June 2008.
Consultation documents:
Click here for Full Guideline
Click here for NICE Guideline
Click here for Comments Proforma
Click here for Excluded Studies
Click here for Search Strategies
Click here for Evidence Table
Click here for Health Economics Tables
Proactive case finding and retention and improving access to services: consultation on the draft guidance (23rd April 2008)
Consultation on the draft guidance for the NHS and other sectors on what works in identifying and supporting people most at risk of dying prematurely from CVD and other smoking related diseases. Closing date for comments is 22nd May 2008.
Click here for Draft Guidance
Click here for Comments Form
Commissioning Guides (April 2008)
NICE have updated and published a number of commissioning guides which are available to download on their site.
Click here for the Guides
Rheumatoid arthritis (refractory) - abatacept. Technology appraisal TA141 (23rd April 2008)
Abatacept is not recommended for people with moderate to severe active rheumatoid arthritis who have already tried drugs known as disease-modifying anti-rheumatic drugs (including a 'TNF inhibitor' drug), which didn't work or weren't suitable. Healthcare professionals should not stop prescribing abatacept for people who were already taking it when the guidance was issued. These patients should be able to carry on taking abatacept until they and their specialist decide that it is the right time to stop treatment.
Click here for Full Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for Costing Statement
Click here for Audit Support
Perioperative hypothermia (inadvertent). Clinical Guideline CG65 (23rd April 2008)
This guidance covers the care and treatment of people who are having an operation in hospital, in the NHS in England and Wales, to reduce their risk of getting cold before, during or after their operation.
Click here for NICE Guideline
Click here for Full Guideline
Click here for Full Guideline Appendices
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance (professionals)
Click here for Understanding NICE Guidance (public)
Click here for Cost Template
Click here for Cost Report
Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. Intervention Procedure Guidance IPG258 (23rd April 2008)
Intraoperative blood cell salvage involves the collection of the solid components of the blood lost during an operation which is then transfused back to the same patient.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Consultation Comments
Interstitial photodynamic therapy for malignant parotid tumours. Intervention Procedure Guidance IPG259 (23rd April 2008)
The parotid glands are located in front of the ears and help to produce saliva. A tumour in a parotid gland usually causes a painless swelling on the side of the face where the affected gland is. Only a small number of these tumours are cancerous. In photodynamic therapy (usually abbreviated to PDT), a drug called a 'photosensitising agent' is injected into a vein. A few days later, needles are inserted into the tumour and a special light is shone through them. The light causes the photosensitising agent to destroy the tumour cells.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Audit Support
Click here for Consultation Comments
Colitis (ulcerative) - infliximab. Technology Appraisal TA140 (23rd April 2008)
Infliximab is not recommended for people with subacute, moderately to severely active ulcerative colitis. Subacute ulcerative colitis is defined as ulcerative colitis that would normally be managed without needing to stay in hospital overnight or having urgent surgery.
Click here for NICE Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for udit Support
Click here for Costing Statement
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. Intervention Procedure Guidance IPG257 (23rd April 2008)
Type 1 diabetes mellitus is a condition that occurs when the body does not produce enough insulin (a substance that helps control sugar balance in the body). It is usually treatable with insulin injections, but people with type 1 diabetes mellitus have an increased risk of other health problems, such heart disease. Allogeneic pancreatic islet cell transplantation involves the removal of cells called islet cells, which are responsible for the production of insulin, from human donors. These cells are inserted into the patient's liver to restart insulin production within the body. However, patients who have this procedure will need to take medications to help their bodies' immune system to accept the cells.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Audit Support
Click here for Consultation Comments
NICE have been asked to develop a clinical practice guideline on the diagnosis, prevention and management of delirium for use in the NHS in England and Wales. The draft scope defines what aspects of care the guideline will cover and to whom it will apply. Registered stakeholders for this guideline are invited to submit comments on the scope and may suggest clinical questions that could be answered in the guideline. Closing date for comments is 14th May 2008.
Click here for the Consultation
Click here for the Comments proforma
Critical illness rehabilitation: scope consultation (17th April 2008)
NICE have been asked to develop a clinical practice guideline on Critical illness rehabilitation for use in the NHS in England, Wales and Northern Ireland. The draft scope defines what aspects of care the guideline will cover and to whom it will apply. Registered stakeholders for the Critical illness rehabilitation guideline are invited to submit comments on the scope and may suggest clinical questions that could be answered in the guideline. Closing date for comments is 15th May 2008.
Click here for the Consultation
Click here for the Comments proforma
Surgical site infection: consultation (22nd April 2008)
A clinical practice guideline on surgical site infection is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations via this website. Although individuals and organisations not registered as stakeholders are able to comment, we recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. We work closely with stakeholder organisations and take their views very seriously. Closing date for comments is 16th June 2008.
Consultation documents:
Click here for Full Guideline
Click here for NICE Guideline
Click here for Comments Proforma
Click here for Excluded Studies
Click here for Search Strategies
Click here for Evidence Table
Click here for Health Economics Tables
Proactive case finding and retention and improving access to services: consultation on the draft guidance (23rd April 2008)
Consultation on the draft guidance for the NHS and other sectors on what works in identifying and supporting people most at risk of dying prematurely from CVD and other smoking related diseases. Closing date for comments is 22nd May 2008.
Click here for Draft Guidance
Click here for Comments Form
Commissioning Guides (April 2008)
NICE have updated and published a number of commissioning guides which are available to download on their site.
Click here for the Guides
Rheumatoid arthritis (refractory) - abatacept. Technology appraisal TA141 (23rd April 2008)
Abatacept is not recommended for people with moderate to severe active rheumatoid arthritis who have already tried drugs known as disease-modifying anti-rheumatic drugs (including a 'TNF inhibitor' drug), which didn't work or weren't suitable. Healthcare professionals should not stop prescribing abatacept for people who were already taking it when the guidance was issued. These patients should be able to carry on taking abatacept until they and their specialist decide that it is the right time to stop treatment.
Click here for Full Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for Costing Statement
Click here for Audit Support
Perioperative hypothermia (inadvertent). Clinical Guideline CG65 (23rd April 2008)
This guidance covers the care and treatment of people who are having an operation in hospital, in the NHS in England and Wales, to reduce their risk of getting cold before, during or after their operation.
Click here for NICE Guideline
Click here for Full Guideline
Click here for Full Guideline Appendices
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance (professionals)
Click here for Understanding NICE Guidance (public)
Click here for Cost Template
Click here for Cost Report
Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. Intervention Procedure Guidance IPG258 (23rd April 2008)
Intraoperative blood cell salvage involves the collection of the solid components of the blood lost during an operation which is then transfused back to the same patient.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Consultation Comments
Interstitial photodynamic therapy for malignant parotid tumours. Intervention Procedure Guidance IPG259 (23rd April 2008)
The parotid glands are located in front of the ears and help to produce saliva. A tumour in a parotid gland usually causes a painless swelling on the side of the face where the affected gland is. Only a small number of these tumours are cancerous. In photodynamic therapy (usually abbreviated to PDT), a drug called a 'photosensitising agent' is injected into a vein. A few days later, needles are inserted into the tumour and a special light is shone through them. The light causes the photosensitising agent to destroy the tumour cells.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Audit Support
Click here for Consultation Comments
Colitis (ulcerative) - infliximab. Technology Appraisal TA140 (23rd April 2008)
Infliximab is not recommended for people with subacute, moderately to severely active ulcerative colitis. Subacute ulcerative colitis is defined as ulcerative colitis that would normally be managed without needing to stay in hospital overnight or having urgent surgery.
Click here for NICE Guidance
Click here for Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for udit Support
Click here for Costing Statement
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. Intervention Procedure Guidance IPG257 (23rd April 2008)
Type 1 diabetes mellitus is a condition that occurs when the body does not produce enough insulin (a substance that helps control sugar balance in the body). It is usually treatable with insulin injections, but people with type 1 diabetes mellitus have an increased risk of other health problems, such heart disease. Allogeneic pancreatic islet cell transplantation involves the removal of cells called islet cells, which are responsible for the production of insulin, from human donors. These cells are inserted into the patient's liver to restart insulin production within the body. However, patients who have this procedure will need to take medications to help their bodies' immune system to accept the cells.
Click here for Guidance
Click here for Understanding NICE Guidance
Click here for Audit Support
Click here for Consultation Comments
No comments:
Post a Comment